Table 4.

One-way sensitivity analysis of important factors

Factor	Cost-effectiveness ratio ($/QALY gained)
Base case analysis	3,016
Simulation model
Log-normal	2,874
Weibull	3,341
Recurrence rate (95% CI: 30.5% - 38.8%)	2,446 ‒ 3,891
Utility
Remission after surgery (95% CI: 0.788 - 0.898)	2,825 ‒ 3,231
Metastasis (95% CI: 0.231 - 0.473)	2,998 ‒ 3,032
QALY gained (95% CI: 0.48 – 1.96)	1,901 ‒ 7,696
Recurrence cost (95% CI: $2,032 - $2,422)	2,834 ‒ 3,149
End of life cost (95% CI: $3,997 - $4,766)	2,682 ‒ 3,302
Exclusion of end-of-life costs due to gastric cancer	3,677
S-1 cost (95% CI: $4,322 - $4,772)	2,810 ‒ 3,173
Total cost difference (95% CI: $2,911 - $4,512 )	2,347 ‒ 3,638

Discount rate: 3% for both cost and effectiveness, Period: lifetime.